Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 15, 2026, 5:21 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 409–432 of 12,658 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Malignant Epithelial Neoplasms Clear all
Recruiting Phase 3 Interventional

A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)

NCT06875310
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Adagrasib, Pembrolizumab, Carboplatin, Pemetrexed, Placebo, Cisplatin
Drug
Lead sponsor
Mirati Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
630 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
52
States / cities
Birmingham, Alabama • Springdale, Arkansas • Fullerton, California + 46 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 15, 2026, 5:21 PM EDT
Completed Phase 2 Interventional Results available

Pilot Study of Bisphosphonate Therapy (Zoledronic Acid) in Patients With Malignant Mesothelioma (UAB 0901)

NCT01204203
View directory record Official record
Conditions
Mesothelioma
Interventions
Zometa
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated May 24, 2017 · Synced Oct 15, 2026, 5:21 PM EDT
Active, not recruiting Phase 3 Interventional

Evaluate Durvalumab and Tremelimumab +/- Lenvatinib in Combination With TACE in Patients With Locoregional HCC

NCT05301842
View directory record Official record
Conditions
Hepatocellular Carcinoma
Interventions
Tremelimumab, Durvalumab, Transarterial Chemoembolization (TACE), Lenvatinib
Drug · Procedure
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 120 Years
Enrollment
760 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
12
States / cities
Birmingham, Alabama • Mobile, Alabama • Yuma, Arizona + 9 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Oct 15, 2026, 5:21 PM EDT
Recruiting Phase 2 Interventional

Testing Less Intensive Radiation With Chemotherapy to Treat Low-risk Patients With HPV-positive Oropharyngeal Cancer

NCT04444869
View directory record Official record
Conditions
Cancer of the Head and Neck, Oropharynx Cancer, HPV Positive Oropharyngeal Squamous Cell Carcinoma, Throat Carcinoma
Interventions
Cisplatin injection
Drug
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated May 17, 2024 · Synced Oct 15, 2026, 5:21 PM EDT
Completed Phase 3 Interventional Results available

Phase III Study to Determine Efficacy of Durvalumab in Stage II-III Non-small Cell Lung Cancer (NSCLC) After Curative Intent Therapy.

NCT04642469
View directory record Official record
Conditions
Carcinoma, Non- Small Cell Lung
Interventions
Durvalumab, Placebo
Drug · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
10
States / cities
Long Beach, California • Los Angeles, California • Daytona Beach, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2024 · Synced Oct 15, 2026, 5:21 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Endoscopic Ultrasound (EUS)-Guided Ablation of Pancreatic Cysts

NCT01643460
View directory record Official record
Conditions
Pancreatic Cyst, Pancreatic Intraductal Papillary-Mucinous Neoplasm, Cystadenoma, Mucinous, Papillary Mucinous Cystadenoma, Borderline Malignancy
Interventions
98% Ethanol & Paclitaxel injection
Procedure
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2022
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Apr 14, 2022 · Synced Oct 15, 2026, 5:21 PM EDT
Not listed Not applicable Interventional

Contrast-Enhanced CT and MRI in Diagnosing and Staging Liver Cancer Using UNOS Policy

NCT01082224
View directory record Official record
Conditions
Liver Cancer
Interventions
iodinated contrast dye, motexafin gadolinium, Eovist-enhanced MRI
Drug · Other
Lead sponsor
American College of Radiology Imaging Network
Network
Eligibility
18 Years and older
Enrollment
440 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2023
U.S. locations
9
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Los Angeles, California + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2023 · Synced Oct 15, 2026, 5:21 PM EDT
Not yet recruiting Not applicable Interventional

SOLIS: Single-Dose Radiotherapy With Omission of Lumpectomy for Intact Small Breast Cancers

NCT07844759
View directory record Official record
Conditions
Breast Cancer, Early-Stage Breast Carcinoma, Hormone Receptor-Positive Breast Cancer, HER2-Negative Breast Cancer
Interventions
Stereotactic Radiation Therapy, Endocrine Therapy
Radiation · Drug
Lead sponsor
Renaissance Institute of Precision Oncology and Radiosurgery
Other
Eligibility
50 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2032
U.S. locations
1
States / cities
Winter Park, Florida
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 15, 2026, 5:21 PM EDT
Terminated Phase 1 Interventional

A Safety Study of SGN-CD47M in Patients With Solid Tumors

NCT03957096
View directory record Official record
Conditions
Soft Tissue Sarcoma, Colorectal Cancer, Head and Neck Squamous Cell Carcinoma, Non-small Cell Lung Carcinoma, Breast Carcinoma, Ovarian Carcinoma, Exocrine Pancreatic Carcinoma, Gastric Carcinoma, Melanoma
Interventions
SGN-CD47M
Drug
Lead sponsor
Seagen Inc.
Industry
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
5
States / cities
Cleveland, Ohio • Portland, Oregon • Nashville, Tennessee + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2020 · Synced Oct 15, 2026, 5:21 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Malignant Pleural Disease Treated With Autologous T Cells Genetically Engineered to Target the Cancer-Cell Surface Antigen Mesothelin

NCT02414269
View directory record Official record
Conditions
Malignant Pleural Disease, Mesothelioma, Metastases, Lung Cancer, Breast Cancer
Interventions
iCasp9M28z T cell infusions, cyclophosphamide, pembrolizumab
Genetic · Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2027
U.S. locations
6
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Oct 15, 2026, 5:21 PM EDT
Recruiting Phase 2 Interventional

Combination of TATE and PD-1 Inhibitor in Liver Cancer

NCT03259867
View directory record Official record
Conditions
Hepatocellular Carcinoma, Gastric Cancer
Interventions
Nivolumab Injectable Product, Trans-arterial tirapazamine embolization
Drug · Combination Product
Lead sponsor
Teclison Ltd.
Industry
Eligibility
18 Years to 80 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
3
States / cities
Orange, California • Oklahoma City, Oklahoma • Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced Oct 15, 2026, 5:21 PM EDT
Active, not recruiting Not applicable Interventional

Single Fraction Accelerated Partial Breast Irradiation vs. Five Fraction Accelerated Partial Breast Irradiation for Low-risk Stage 0 and I Breast Carcinoma

NCT04849871
View directory record Official record
Conditions
Breast Carcinoma, Breast Cancer, Stage 0 Breast Cancer, Stage I Breast Cancer
Interventions
External Beam Accelerated Partial Breast Irradiation
Radiation
Lead sponsor
Washington University School of Medicine
Other
Eligibility
50 Years and older · Female only
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Oct 15, 2026, 5:21 PM EDT
Completed Phase 2 Interventional

Gemcitabine in Treating Patients With Advanced Salivary Gland Cancer That Cannot Be Removed During Surgery

NCT00003744
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
gemcitabine
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2004
U.S. locations
6
States / cities
Chicago, Illinois • Boston, Massachusetts • Burlington, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 19, 2017 · Synced Oct 15, 2026, 5:21 PM EDT
Recruiting Not applicable Interventional

Feasibility of Intra- and Post-operative Microdialysis During Neurosurgery for Central Nervous System Lesions

NCT04047264
View directory record Official record
Conditions
Glioma, Glioblastoma, Metastatic Malignant Neoplasm in the Brain
Interventions
Microdialysis, Magnetic Resonance Imaging, Computed Tomography
Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Oct 15, 2026, 5:21 PM EDT
Withdrawn Phase 2 Interventional

Comparative Study of Cetuximab and Radiation Vs Surgery Before or After Radiation in Patients With Colorectal Carcinoma

NCT00725400
View directory record Official record
Conditions
Colorectal Carcinoma
Interventions
Cetuximab and Radiation Therapy, Surgery and Radiation Therapy
Other · Procedure
Lead sponsor
American Scitech International
Other
Eligibility
40 Years and older
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Englishtown, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 20, 2011 · Synced Oct 15, 2026, 5:21 PM EDT
Completed Phase 2 Interventional Results available

Bevacizumab in Treating Patients With Recurrent or Persistent Endometrial Cancer

NCT00301964
View directory record Official record
Conditions
Recurrent Endometrial Carcinoma
Interventions
bevacizumab, laboratory biomarker analysis
Biological · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 24, 2019 · Synced Oct 15, 2026, 5:21 PM EDT
Completed Phase 3 Interventional Results available

A Study of Atezolizumab Plus Bevacizumab Versus Active Surveillance as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Surgical Resection or Ablation

NCT04102098
View directory record Official record
Conditions
Carcinoma, Hepatocellular
Interventions
Atezolizumab, Bevacizumab
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
668 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
8
States / cities
Los Angeles, California • Baltimore, Maryland • Detroit, Michigan + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 18, 2026 · Synced Oct 15, 2026, 5:21 PM EDT
Recruiting Phase 2 Interventional

Talazoparib With Androgen Deprivation Therapy and Abiraterone for the Treatment of Castration Sensitive Prostate Cancer

NCT04734730
View directory record Official record
Conditions
Castration-Sensitive Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Stage IV Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8
Interventions
Abiraterone Acetate, Bicalutamide, Degarelix, Goserelin Acetate, Leuprolide Acetate, Prednisone, Questionnaire Administration, Talazoparib
Drug · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older · Male only
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Jan 28, 2026 · Synced Oct 15, 2026, 5:21 PM EDT
Completed Phase 2 Interventional Results available

Pemetrexed Disodium With or Without Erlotinib Hydrochloride in Treating Patients With Stage IIIB-IV or Recurrent Non-Small Cell Lung Cancer

NCT00950365
View directory record Official record
Conditions
Bronchioloalveolar Carcinoma, Large Cell Lung Carcinoma, Lung Adenocarcinoma, Recurrent Non-Small Cell Lung Carcinoma, Stage IIIB Non-Small Cell Lung Cancer, Stage IV Non-Small Cell Lung Cancer
Interventions
Erlotinib Hydrochloride, Laboratory Biomarker Analysis, Pemetrexed Disodium
Drug · Other
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
18 Years and older
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2017
U.S. locations
5
States / cities
Sacramento, California • Worcester, Massachusetts • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Sep 16, 2020 · Synced Oct 15, 2026, 5:21 PM EDT
Completed Not applicable Interventional

Positron Emission Tomography in Determining Stage of Esophageal Cancer

NCT00004867
View directory record Official record
Conditions
Esophageal Cancer
Interventions
conventional surgery, positron emission tomography, radionuclide imaging, fludeoxyglucose F 18, chemotherapy, Radiotherapy
Procedure · Radiation · Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
235 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2009
U.S. locations
35
States / cities
Birmingham, Alabama • Mobile, Alabama • Los Angeles, California + 26 more
Source: ClinicalTrials.gov public record
Updated Jan 24, 2017 · Synced Oct 15, 2026, 5:21 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Ipatasertib in Combination With Carboplatin, Carboplatin/Paclitaxel, or Capecitabine/Atezolizumab in Treating Patients With Metastatic Triple Negative Breast Cancer

NCT03853707
View directory record Official record
Conditions
Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Triple-Negative Breast Carcinoma, Prognostic Stage IV Breast Cancer AJCC v8
Interventions
Atezolizumab, Capecitabine, Carboplatin, Ipatasertib, Paclitaxel, Quality-of-Life Assessment, Questionnaire Administration
Drug · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Feb 20, 2024 · Synced Oct 15, 2026, 5:21 PM EDT
Terminated Phase 1 Interventional Results available

Sirolimus and Durvalumab for the Treatment of Stage I-IIIA Non-small Cell Lung Cancer

NCT04348292
View directory record Official record
Conditions
Lung Non-Small Cell Carcinoma, Stage I Lung Cancer AJCC v8, Stage IA1 Lung Cancer AJCC v8, Stage IA2 Lung Cancer AJCC v8, Stage IA3 Lung Cancer AJCC v8, Stage IB Lung Cancer AJCC v8, Stage II Lung Cancer AJCC v8, Stage IIA Lung Cancer AJCC v8, Stage IIB Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8
Interventions
Durvalumab, Sirolimus
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Aug 22, 2024 · Synced Oct 15, 2026, 5:21 PM EDT
Not listed Early Phase 1 Interventional Accepts healthy volunteers

Topical Ascorbic Acid for Treatment of Squamous Cell Skin Cancer

NCT05932511
View directory record Official record
Conditions
Squamous Cell Cancer, Squamous Cell Carcinoma, Skin Cancer, Non-melanoma Skin Cancer
Interventions
30% ascorbic acid in DMSO
Drug
Lead sponsor
Center for Biomedical Research, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Boise, Idaho
Source: ClinicalTrials.gov public record
Updated Aug 30, 2023 · Synced Oct 15, 2026, 5:21 PM EDT
Terminated Phase 1Phase 2 Interventional

Satraplatin for Locally Advanced Non-Small Cell Lung Cancer With Simultaneous Radiotherapy

NCT00093132
View directory record Official record
Conditions
Carcinoma, Non-small Cell Lung, Lung Cancer
Interventions
Satraplatin
Drug
Lead sponsor
Agennix
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Aug 17, 2012 · Synced Oct 15, 2026, 5:21 PM EDT